17,261 trials
Neoplasms, Breast
Primary: Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee — 2; 12; 58; 54…
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Lupus Erythematosus, Systemic
Primary: Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24. — -17.2…
Carcinoma of the Appendix · Colorectal Cancer
Primary: Time to Progression — 0.775 years
Non-Hodgkin's Lymphoma (NHL)
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR), as Determined by the International Working Group (IWG)…
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Type 2 Diabetes Mellitus
Primary: Change in Haemoglobin A1c (HbA1c) — 0.0; -0.3; 0.1; 0.2 Percentage
Facial Rhytidectomy (Face-lift)
Primary: Visual Comparison of Ecchymosis at Postoperative Day 3 — 5; 12; 11; 0 participants — p=0.143
Subjective Tinnitus
Primary: Change in THI (Tinnitus Handicap Inventory) — -5; -6; -10; -6 units on a scale — p=0.944
CRPS
Primary: Epidural Medication Consumption Rate — 6.40; 5.77 mL/h — p=0.003
Breast Cancer · Breast Neoplasm
Primary: Number of Participants With Adverse Events — 9; 20 Participants
Pancreatic Neuroendocrine Tumors
Primary: Clinical Benefit Response Rate (CBR) — 75.0 percentage of participants
Japanese Encephalitis
Primary: Number of Participants With Treatment Emergent Adverse Events Following Vaccination With Either ChimeriVax™ JE or JE Inactivated Mouse Brain Derived Vaccine — 2; 2; 1; 0…
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Common Cold
Primary: Investigator's End of Study Assessment of Treatment — 163; 149 participants — p=0.0096